Department of Surgery/Transplant, University of Illinois at Chicago, Chicago, IL, 60612, USA,
Curr Diab Rep. 2013 Oct;13(5):723-32. doi: 10.1007/s11892-013-0402-z.
Human islet transplantation is an effective and promising therapy for type I diabetes. However, long-term insulin independence is both difficult to achieve and inconsistent. De novo or early administration of incretin-based drugs is being explored for improving islet engraftment. In addition to its glucose-dependent insulinotropic effects, incretins also lower postprandial glucose excursion by inhibiting glucagon secretion, delaying gastric emptying, and can protect beta-cell function. Incretin therapy has so far proven clinically safe and tolerable with little hypoglycemic risk. The present review aims to highlight the new frontiers in research involving incretins from both in vitro and in vivo animal studies in the field of islet transplant. It also provides an overview of the current clinical status of incretin usage in islet transplantation in the management of type I diabetes.
人胰岛移植是治疗 1 型糖尿病的一种有效且有前途的疗法。然而，长期的胰岛素独立性既难以实现，也不一致。新的或早期使用基于肠促胰岛素的药物正在探索中，以改善胰岛移植。除了葡萄糖依赖性胰岛素促分泌作用外，肠促胰岛素还通过抑制胰高血糖素分泌、延缓胃排空来降低餐后血糖波动，并且可以保护β细胞功能。迄今为止，肠促胰岛素治疗在临床中已被证明是安全且耐受的，低血糖风险很小。本综述旨在强调在胰岛移植领域中，从体外和体内动物研究两个方面，肠促胰岛素研究的新前沿。它还概述了肠促胰岛素在 1 型糖尿病管理中的胰岛移植中的临床应用现状。
